Xtant Medical Holdings, Inc., a global company operating in surgical solutions for spinal, orthopedic, and wound care, has announced the commercial release of its CollagenX™. This product is a combination of bovine collagen particles and is designed to help close surgical wounds, which promotes healing and reduces the risk of wound reopening, as well as prevents infections.
CollagenX has the capability to be a valuable addition to all types of cases currently treated by Xtant's biologics portfolio, including those related to spinal, orthopedic, and wound care. It could also be utilized in a broad range of procedures in other surgical specialties, expanding its applications beyond just Xtant's core areas.
Xtant Medical is driven by a mission to honor the gift of donation and help our patients live fuller, healthier lives. As a global medical technology company, they focus on designing, developing, and bringing to market a broad range of orthobiologics for chronic and surgical wound care, sports medicine, and spinal implant systems. Their dedicated and talented team operates with the utmost integrity to serve and support their customers.
Executive Statement
According to Sean Browne, President and CEO of Xtant Medical, the commercial launch of CollagenX for surgical wound closure enhances our extensive orthobiologics portfolio and demonstrates their dedication to innovation in meeting the diverse needs of surgeons and patients. As one of the few fully vertically integrated regenerative medicine firms, they are uniquely equipped to deliver the quality and consistency that can significantly improve patient outcomes.
